Uses Of Lp-pla2 In Combination To Assess Coronary Risk

Abstract

This invention relates to a method for assessing risk of Coronary Vascular Disease (CVD). Specifically, it relates to utilizing risk assessment from both Lipoprotein Associated Phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) in combination. In addition the invention relates to a method for assessing risk of Coronary Vascular Disease (CVD) in a patient with low to normal Low Density Lipoprotein Cholesterol (LDL) levels utilizing both LDL and Lipoprotein Associated Phospholipase A2 (Lp-PLA2). Moreover, the invention relates to the use of risk associated with Lp-PLA2, CRP and LDL in combination and specific ranges thereof to predict Coronary Vascular Disease.


Claims
Download PDF
Document Preview
Document History
  • Publication: Mar 24, 2011
  • Application: Nov 24, 2010
    US US 95368710 A
  • Priority: Nov 24, 2010
    US US 95368710 A
  • Priority: Apr 1, 2004
    US US 55208404 A
  • Priority: Apr 1, 2004
    US US 2004/0010039 W
  • Priority: Apr 1, 2003
    US US 45978503 P

Download Citation


Sign in to the Lens

Feedback